Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D ...

Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...

WASHINGTON -- An investigational dual therapy appeared to show antiviral activity in patients with chronic hepatitis D virus (HDV) infection, according to the phase II SOLSTICE trial.

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced it will present Phase I data for BW-20805 at the American ...

Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination ...

In everyday life, when things turn out the opposite of what you expect, it's usually a cause for frustration. In science, it's often the starting point for discovery. That's what happened to a team of ...

When compared to published data with inclisiran, a small interfering RNA (siRNA) molecule that inhibits production of the ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has ...

Please provide your email address to receive an email when new articles are posted on . Investigational therapies to lower Lp(a) include antisense oligonucleotide therapies and small interfering RNA ...